These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37697390)

  • 21. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).
    Cohen EEW; Bell RB; Bifulco CB; Burtness B; Gillison ML; Harrington KJ; Le QT; Lee NY; Leidner R; Lewis RL; Licitra L; Mehanna H; Mell LK; Raben A; Sikora AG; Uppaluri R; Whitworth F; Zandberg DP; Ferris RL
    J Immunother Cancer; 2019 Jul; 7(1):184. PubMed ID: 31307547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan.
    Sano D; Tokuhisa M; Takahashi H; Hatano T; Nishimura G; Ichikawa Y; Oridate N
    Anticancer Res; 2022 Sep; 42(9):4477-4484. PubMed ID: 36039457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis.
    Kao HF; Liao BC; Huang YL; Huang HC; Chen CN; Chen TC; Hong YJ; Chan CY; Chia JS; Hong RL
    Clin Cancer Res; 2022 Apr; 28(8):1560-1571. PubMed ID: 35046059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune checkpoint inhibitor-induced diabetes mellitus with pembrolizumab.
    Zand Irani A; Almuwais A; Gibbons H
    BMJ Case Rep; 2022 Jan; 15(1):. PubMed ID: 35039353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report.
    Wang C; Erick Elkowitz D; Esposito MJ; Shah RD; Tannous H; Barilla-Labarca ML; Seetharamu N
    Ther Adv Rare Dis; 2023; 4():26330040231190661. PubMed ID: 37576433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Late-onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer.
    Ichihara S; Kunishige M; Kadota N; Okano Y; Machida H; Hatakeyama N; Naruse K; Shinohara T; Takeuchi E
    Thorac Cancer; 2023 Jan; 14(1):81-84. PubMed ID: 36411591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A Case of Severe Skin Disorder during Pembrolizumab Treatment for Recurrent Maxillary Gingival Carcinoma].
    Okuma S; Karino M; Matsuda Y; Tatsumi H; Okui T; Kanno T
    Gan To Kagaku Ryoho; 2024 Mar; 51(3):343-345. PubMed ID: 38494826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma.
    Wu L; Li B
    Diabetes Metab Syndr Obes; 2021; 14():753-757. PubMed ID: 33628041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pembrolizumab in the first-line treatment of advanced head and neck cancer.
    de Sousa LG; Ferrarotto R
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1321-1331. PubMed ID: 34689660
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Case Report of Pembrolizumab-Induced Allergic Hepatitis.
    Nakatani S; Fukushima M; Akahani S
    Cureus; 2024 Jul; 16(7):e64703. PubMed ID: 39156358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
    Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
    J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
    Lang Y; Dong D; Wu B
    Clin Drug Investig; 2020 Dec; 40(12):1137-1146. PubMed ID: 33095408
    [TBL] [Abstract][Full Text] [Related]  

  • 34. First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
    Takahashi S; Oridate N; Tanaka K; Shimizu Y; Fujimoto Y; Matsumoto K; Yokota T; Yamazaki T; Takahashi M; Ueda T; Hanai N; Yamaguchi H; Hara H; Yoshizaki T; Yasumatsu R; Nakayama M; Shiga K; Fujii T; Mitsugi K; Takahashi K; Nohata N; Gumuscu B; Swaby RF; Tahara M
    Int J Clin Oncol; 2022 Dec; 27(12):1805-1817. PubMed ID: 36264378
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A patient with advanced lung squamous cell carcinoma who failed to benefit from albumin bound paclitaxel plus pembrolizumab achieved partial response with second-line treatment of docetaxel plus pembrolizumab: a case report.
    Zhang F; Xu Y; Guo S; Li S; Ma K; Wang J; Wei S
    Ann Palliat Med; 2022 Sep; 11(9):3020-3027. PubMed ID: 36217630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
    Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Case of Lung Adenocarcinoma with Long-Term Response after Late-Onset Pembrolizumab-Induced Acute Adrenal Insufficiency.
    Sonehara K; Tateishi K; Hirabayashi T; Araki T; Ikuyama Y; Machida R; Hanaoka M
    Case Rep Oncol; 2021; 14(1):1-7. PubMed ID: 33613234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and literature review.
    Lin SH; Zhang A; Li LZ; Zhao LC; Wu LX; Fang CT
    BMC Endocr Disord; 2022 Sep; 22(1):239. PubMed ID: 36153581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
    Rodriguez CP; Wu QV; Voutsinas J; Fromm JR; Jiang X; Pillarisetty VG; Lee SM; Santana-Davila R; Goulart B; Baik CS; Chow LQM; Eaton K; Martins R
    Clin Cancer Res; 2020 Feb; 26(4):837-845. PubMed ID: 31796519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
    J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.